NCT01454479View on ClinicalTrials.gov

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

PHASE1UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2014

Conditions
Recurrent Endometrial Cancer
Interventions
DRUG

Lapatinib and ixempra

Ixabepilone 40 mg/m2 Lapatinib 250 mg

Sponsors
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Hung-Hsueh Chou

OTHER

NCT01454479 - A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma | Biotech Hunter | Biotech Hunter